Moderators: mick
Search This Board: 
Created: 08/23/2016 10:37:24 AM - Followers: 15 - Board type: Free - Posts Today: 0
 

Image result for oncotelic therapeutics

Reverse Merged with MATEON THERAPEUTICS Formally MATN

Oncotelic – Welcome to Oncotelic

$11 Billion Target Markets - 100+ Patent Applications - 2 Key Clinical Programs - 30+ Years Experience

Mateon has three major business segments: 1) PointR- developer of vision grid/cluster computing/AI to support drug development. 2) Mateon/Oxigene- developer of Vascular Disrupting Agent (CA4P and Oxi4503). FDA granted CA4P rare pediatric designation for pediatric melanoma in 2020 and OXi4503 rare pediatric designation for pediatric ALL. 3) Oncotelic- developer of OT-101 - an antisense against TGF-beta- for the treatment of cancers. OT-101 completed phase 2 with good safety and efficacy against pancreatic cancer, glioblastoma, and melanoma. OT-101 also been granted rare pediatric designation against pediatric DIPG in 2019. OT-101 is also being deployed against COVID-19. OT-101 is in phase 2 clinical trial against COVID. We are also developing Artemisinin in phase 4 clinical trial against COVID. It is approved by India for symptoms frequently observed in COVID. It is being launch by end of 2020. Global launch will be soon after.

 

Oncotelic (formerly known as Mateon Therapeutics, Inc.) was created by the 2019 reverse merger with Oncotelic, which became a wholly owned subsidiary of Oncotelic, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. OT-101 also has shown activity against SARS-CoV-2 and COVID-19. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503). For more information, please visit www.oncotelic.com and www.Oncotelic.com.

 

ARTIShield ™/ARTIVedaTM- an Ethnobiology Drug

Mateon is pursuing several avenues with respect to the development and commercialization of ARTIShield in the treatment of COVID-19. ARTIShield is Ayurveda - Dvipaantara Damanaka - and is labeled as a capsule containing Artemisia Powder 500mg. It is a demonstration of how Ethnobiology can be used to drive drug development against emerging pandemics.

The classical pharmaceutical regulatory pathways have failed to provide fast-track to treatment and vaccines. Government resources have concentrated on a few candidates most of which have failed. The Ayurvedic medicine route is proving to be an accelerated pathway to deploy a well-known, abundantly available and cost effective Ayurvedic medicine that is safe and being proven in-vitro and large-scale clinical trial to be effective.

ARTIShield /ARTIVeda - Commercialization in India

Mateon announced that ARTIShield /ARTIVeda has been approved for manufacture and marketing by the Ministry of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy) in India for the treatment of various symptoms including fever and inflammation, which can be associated with COVID-19. ARTIShield is in co-development with Windlas Biotech Pvt. Ltd., Mateon’s commercial partner for India and is designed to be a readily available and cost-effective agent to combat COVID-19. ARTIVeda is the tradename for India and ArtiShieldTM is the tradename for outside of India. Mateon expects sales will commence in India before year end.

ARTI-19 Multi-national Phase IV Trial, Currently in India

Mateon announced the enrollment of its first patient in a Phase IV study ARTI-19, “A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19”. This trial will compare the efficacy of oral doses with standard-of-care (SOC) versus SOC alone. This is a global study with India to contribute at least 300 patients to the total aggregate of 3000 patients. We expect preliminary top-line data for ARTI-19 sometime between Q420 and Q121.

About OT-101

OT-101 is an antisense against the host TGF-β protein required for viral replication and its overexpression likely to cause the wide range of clinical symptoms associated with COVID-19 including Kawasaki syndrome (Fatih M. Uckun, Vuong Trieu. Targeting Transforming Growth Factor-beta for Treatment of COVID-19-associated Kawasaki Disease in Children. Clin Res Pediatr 2020; 3(1): 1-3) and acute respiratory distress syndrome (ARDS) (Fatih M. Uckun, Larn Hwang, Vuong Trieu. Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ARDS in COVID-19. Clin. Invest. (Lond.) 2020; 10(2), 167-176. DOI: 10.4172/ Clinical-Investigation.1000166.).

TGF-β is elevated in COVID-19 (Xiong Y. et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging Microbes & infections 2020; 9:1, 761-770, DOI: 10.1080/22221751.2020.1747363. Agrati C. et al. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). Cell Death & Differentiation 2020; https://doi.org/10.1038/s41418-020-0572-6.).

OT-101 is also being developed as an adjuvant for second generation COVID-19 vaccine. To avoid the two potential issues with 1st generation vaccine against COVID-19, we will be combining the 1st generation COVID-19 DNA vaccine with a TGF-β inhibitor (OT-101) to stimulate a strong immune response while suppressing the IgA class switching

ArtiVeda/ArtiShield – a natural derivative from the plant Artemisia – Artemisinin has shown to be highly potent at inhibiting the ability of the COVID-19 causing virus to multiply while also having an excellent safety index. Artemisinin derivatives are used to treat malaria. More Information.

OT-101 – an antisense against TGF-β2 – for the treatment of solid tumors with focus on brain cancer in adult and DIPG in children. RPD for pediatric DIPG granted by US FDA. OT-101, also referred to Trabedersen, is a novel antisense oligodeoxynucleotide (ODN) developed by Oncotelic for the treatment of patients with pancreatic carcinoma, malignant melanoma, colorectal carcinoma, high-grade glioma (HGG), and other transforming growth factor beta 2 (TGF-β2) overexpressing malignancies (e.g., prostate carcinoma, renal cell carcinoma, etc.).

Trabedersen is a synthetic 18-mer phosphorothioate oligodeoxynucleotide (S-ODN) complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene. Cancers overexpress TGF-β, which suppresses host innate immune response to the cancers. Treatment with OT-101 lifts the TGF-β cloaking effect and allows innate or therapeutic immunity to attack and eliminate the cancers.

We have completed phase 2 for pancreatic cancer and melanoma, and phase 2 in glioblastoma with robust efficacy and safety.

OT-101 – an antisense against TGF-β2 –for the treatment of various viruses, including the SARS and the current COVID-19, on its own and in conjunction with other compounds.

CA4P – a vascular disrupting agent (“VDA”)- in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. On May 4th, 2020, FDA granted Rare Pediatric Disease Designation for CA4P/ Fosbretabulin for the treatment of stage IIB–IV melanoma due to genetic mutations that disproportionately affect pediatric patients as a drug for a “rare pediatric disease.”

Oxi4503 – a second generation VDA- for the treatment of liquid tumors with focus on childhood leukemia. US Food and Drug Administration (FDA) granted our request and designate OXi4503 (combretastatin A1-diphosphate; CA1P) for treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients as a drug for a “rare pediatric disease”, as defined in section 529(a)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360ff(a)(3)).

could aggravate the disease through Kawasaki reaction- IgA vasculitis. The company is aggressively pursuing the development of this 2nd generation COVID-19 vaccine expecting that the 1st generation vaccines would not be fully effective and may not be sufficiently protective to counter the current pandemic.

The development of OT-101 is important given the failure of other drugs leaving dexamethasone as the only clinically proven effective drug against COVID-19.

 

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#248
$MATN & $GILD?????,6;41a.m. 07-07-2020 .M. Mateon Therapeutics Appts. mick 07/28/2020 10:25:22 PM
#929
OTLC Oncotelic Therapeutics Inc (QB) mick 07/17/2022 06:16:56 PM
#928
Surprised at the lack of interest i_like_bb_stock 06/20/2022 04:51:58 PM
#927
Looks like we should expect success in the mishe 06/20/2022 01:14:57 PM
#926
Oncotelic Announces Pipeline Presentation and IPO Update of mishe 06/15/2022 04:42:56 PM
#925
Oncotelic Therapeuti (OTLC) mick 06/06/2022 12:03:58 AM
#924
nice news...https://www.otcmarkets.com/stock/OTLC/news/Oncotelic-Therapeutics-Re i_like_bb_stock 05/25/2022 09:11:48 AM
#923
ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO mishe 05/23/2022 01:02:34 PM
#922
Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief mishe 05/04/2022 12:55:19 PM
#921
Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory mishe 05/04/2022 12:54:27 PM
#920
Oncotelic Therapeuti (OTLC) mick 05/01/2022 03:58:26 PM
#919
$OTLC on watch due to Daily Chart increasing PennyMaster 04/20/2022 09:34:05 AM
#918
$OTLC ONCOTELIC PROVIDES YE 2021 FINANCIAL RESULTS COMPARED PennyMaster 04/19/2022 11:18:52 AM
#917
This Little Known Cancer Play has been Crushing PennyMaster 04/14/2022 09:49:22 AM
#916
This Little Known Cancer Play has been Crushing PennyMaster 04/14/2022 09:49:22 AM
#915
$OTLC Company Profile and Technical Chart Analysis PennyMaster 04/13/2022 10:12:54 AM
#914
$OTLC The Accumulation here is off the charts PennyMaster 04/12/2022 09:39:27 AM
#913
$OTLC Chart Forming Beautiful BULL FLAG here! Bullish PennyMaster 04/11/2022 09:16:45 AM
#912
$OTLC Letter to Oncotelic Shareholders on the Recently PennyMaster 04/08/2022 09:42:18 AM
#911
OTLC a bargain here, The JV will i_like_bb_stock 04/07/2022 11:27:55 AM
#910
news https://www.globenewswire.com/news-release/2022/04/07/2418633/0/en/Letter-t i_like_bb_stock 04/07/2022 11:18:08 AM
#909
Oncotelic; Announcing Successful Joint Venture and Diving into mishe 04/04/2022 02:31:03 PM
#908
Oncotelic presentation at MedInvest Pharmaceutical & Biotechnology Investor mishe 04/01/2022 01:17:45 PM
#907
Oncotelic JV Financing: https://www.youtube.com/watch?v=k0Zj59shmw0 mishe 03/21/2022 03:44:03 PM
#906
Oncotelic; Looking at Industry Comparison for the Company: https://www.youtube.c mishe 03/15/2022 04:40:37 PM
#905
Oncotelic; Discussing the Company's Development Pipeline: https://www.youtube.c mishe 03/15/2022 03:51:33 PM
#904
Oncotelic; Diving into the Company's Outlook for 2022: https://www.youtube.com/ mishe 03/15/2022 03:40:43 PM
#903
Oncotelic Therapeuti (OTLC) mick 03/12/2022 03:56:43 PM
#902
Oncotelic to Present New Studies on its TGF-ß mishe 03/10/2022 01:45:40 PM
#901
Questions: I did some DD and was Justin Abreau 03/07/2022 10:57:38 PM
#900
Oncotelic; An Introduction to CFO Amit Shah & mishe 03/02/2022 05:54:58 PM
#899
Oncotelic; An Introduction to CBO GM of AI mishe 02/22/2022 05:46:55 PM
#898
Oncotelic; An Introduction to Chief Clinical Officer Anthony mishe 02/22/2022 05:45:57 PM
#897
Oncotelic Therapeuti (OTLC) mick 02/06/2022 04:59:30 PM
#896
Oncotelic Presenting at BiotechGate Digital Partnering: https://finance.yahoo.co mishe 01/19/2022 11:52:47 AM
#895
$OTLC Oncotelic Initiates Phase 1 Trial Evaluating CA4P TommyBoyTrader9460 01/11/2022 01:45:08 PM
#894
.19's starting to chip away now Screech691 01/10/2022 11:46:14 AM
#893
Thinking the same..chart has been on the climb.. TommyBoyTrader9460 01/10/2022 11:22:09 AM
#892
wouldn't be surprised if it was a fake Screech691 01/10/2022 11:21:17 AM
#891
$OTLC .19 up with a wall..watching for a TommyBoyTrader9460 01/10/2022 11:15:37 AM
#890
looks like we've got the loading block at Screech691 01/10/2022 09:40:34 AM
#889
$OTLC bidders at .18 now..continues to gain strength.. TommyBoyTrader9460 01/07/2022 04:00:45 PM
#888
agreed, just need that dumb seller at .19 Screech691 01/07/2022 02:20:41 PM
#887
Yeah a lot of the OTC is pretty SpaceManTrades 01/07/2022 12:36:59 PM
#886
Quiet trading day..chart still holding strong.. TommyBoyTrader9460 01/07/2022 11:40:02 AM
#885
$OTLC Low Float play, moves on air.. PennyMaster 01/07/2022 10:28:29 AM
#884
I don't see any resistance at all on SpaceManTrades 01/07/2022 09:10:48 AM
#883
$OTLC next leg up on the chart starting, Screech691 01/07/2022 08:42:13 AM
#882
$OTLC Trading very well here..cross the 200 day TommyBoyTrader9460 01/07/2022 06:05:22 AM
#881
$OLTC impressed with today..as .17 broke through TommyBoyTrader9460 01/06/2022 03:49:15 PM
#880
Why 2022 Could Open Gangbusters for Covid Stocks PennyMaster 01/06/2022 03:42:47 PM
Post Subject